Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : R-Ketamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Integration of Introspect’s digital therapeutic with R-ketamine therapy for patients with treatment resistant depression.
Brand Name : PCN-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 09, 2021
Lead Product(s) : R-Ketamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?